2023 World Conference on Lung Cancer (Posters)-P2.06. Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients

P2.06. Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients - PDF(Slides)

Back to course

Pdf Summary

This study provides updated analysis on the use of tislelizumab plus chemotherapy as a first-line treatment for elderly patients with advanced non-small cell lung cancer (NSCLC). Tislelizumab is a monoclonal antibody that targets programmed cell death protein 1 (PD-1) and has been shown to be effective in advanced NSCLC. The study included patients aged 70 and above who had locally advanced or metastatic NSCLC without specific genetic mutations. The treatment regimen consisted of tislelizumab plus nab-paclitaxel, with or without platinum, administered every 3 weeks for 4 cycles, followed by tislelizumab maintenance treatment.<br /><br />The primary endpoint of the study was the objective response rate (ORR), and secondary endpoints included progression-free survival (PFS), disease control rate (DCR), overall survival (OS), duration of response (DoR), and safety. A total of 39 patients were enrolled, with a median age of 74 years and the majority being male. A significant percentage of patients had squamous cell carcinoma and positive PD-L1 expression. <br /><br />Results from the efficacy analysis showed that 22 out of 32 patients achieved a partial response, leading to an ORR of 68.8%. The DCR was 96.9%. The median PFS was 14.3 months, with a 1-year PFS rate of 53.1%. The 1-year and 2-year OS rates were 89.4% and 81.3%, respectively. The median duration of response was 13.05 months.<br /><br />The most common grade 1-2 treatment-related adverse events were anemia, increased AST and ALT levels, and decreased platelet count. The most common immune-related adverse events were mild hypothyroidism and pneumonitis.<br /><br />In conclusion, tislelizumab plus nab-paclitaxel with or without platinum as a first-line treatment for elderly advanced NSCLC patients showed promising results, with a higher ORR, meaningful PFS benefit, and longer DoR. The treatment was generally well-tolerated, with manageable side effects. Further studies are warranted to confirm these findings.

Asset Subtitle

Banzhou Pan

Meta Tag

Speaker Banzhou Pan

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

tislelizumab

chemotherapy

first-line treatment

elderly patients

advanced non-small cell lung cancer

NSCLC

monoclonal antibody

PD-1

objective response rate

progression-free survival